Scholar Rock (SRRK) investor relations material

Executive summary

• FDA approved ISEMBYLD on September 11, 2026, for adults and children aged 2 and older with SMA receiving SMN2-targeted treatment; U.S. launch began in Q3, making it the first and only approved muscle-targeted SMA therapy.

• Initial U.S. patient infusions began in October; enrollment was broad and steady, with treatment-naive patients outnumbering trial/EAP transitions, while payer access and reimbursement lagged demand.

• Apitegromab’s European MAA was resubmitted with an alternate fill-finish facility and Japan’s JNDA was submitted; development continued in younger SMA patients, FSHD and next-generation myostatin inhibition.

Financial highlights

• Q3 net product revenue was $0.57M, compared with none in Q3 2025; reported cost of revenue was $8K, with initial channel inventory shipments contributing to launch-period sales.

• Q3 operating expenses were $106.6M, including $17.9M of non-cash stock-based compensation; operating loss was $106.1M and net loss was $107.2M.

• Q3 R&D expense was $54.1M and SG&A was $52.5M; 9M R&D was $164.2M and SG&A was $153.4M, reflecting commercial-launch infrastructure and headcount.

• 9M net loss was $322.6M, compared with $287.0M in 9M 2025; 9M operating loss was $317.0M.

• Cash, cash equivalents and marketable securities totaled $413.6M at September 30, 2026, versus $367.6M at December 31, 2025.

Outlook and guidance

• Most patients enrolled through October are expected to begin infusions in 2027; prescription-to-infusion timelines can exceed 60–90 days, with management expecting enrollment to grow steadily.

• The ISEMBYLD-specific U.S. J-code is targeted for April 1, 2027; payer policies and hospital formulary processes may reduce access delays, though prior authorization will remain.

• A CHMP opinion for apitegromab is expected in H1 2027; initial Germany launch is expected later in 2027, and Japan launch near year-end 2027, subject to approval and reimbursement processes.

• SRK-439 Phase 1 topline data are expected by year-end 2026, with data planned for release in early 2027.

• Cash, available debt-facility funding and anticipated product revenue are expected to fund operating and capital needs into 2028, subject to assumptions; substantial expenses and operating losses are expected to continue.